The HIV market is set to grow to $27.4bn in 2033. Credit: mayu85 / Shutterstock.com ViiV Healthcare’s long-acting HIV treatment Cabenuva showed superior rates of viral suppression compared with oral ...
The study will also evaluate lung function, changes from baseline in FeNO, and biomarkers of Type 2 inflammation. Credit: NMK-Studio/Shutterstock.com. Clinical-stage biotechnology company Vial has ...
Cerevance will now speak with the FDA about next steps for solengrapas in Parkinson’s disease. Credit: PeopleImages / Shutterstock.com. Boston-based biotech Cerevance’s first-in-class Parkinson’s ...
argenx is already running Phase III trials of Vyvgart in both myositis and Sjögren’s. Credit: Sheldon Cooper/SOPA Images/LightRocket via Getty Images Argenx’s Vyvgart (efgartigimod alfa-fcab) shows ...
Surrozen plans to use the funding to advance SZN-8141 and SZN-8143, as well as for general operational activities. Credit: Sai Thaw Kyar/Shutterstock.com. The US Food and Drug Administration (FDA) has ...
Results from the Phase III TRIUMPH-2 trial (NCT05929079) evaluating retatrutide in overweight patients with T2D were presented at EASD 2026.
Rafael Holdings subsidiary, Cyclo Therapeutics is planning to submit a NDA to US regulators for Trappsol Cyclo in NPC despite the primary endpoint miss. Credit: Kateryna Kon / Shutterstock.com. Rafael ...
The bispecific antibody is intended for treating advanced gastric cancer. Credit: SewCreamStudio/Shutterstock.com. Akeso has commenced a global Phase III clinical ...
ALS is a fatal neurodegenerative condition with no cure and limited treatment options for symptom management. Credit: Andrzej Rostek/Shutterstock.com. VectorY Therapeutics has expanded the study size ...
Oral semaglutide maintains weight-loss progress after injectable GLP-1 therapy, strengthening its case as an oral alternative.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results